Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Merger or Acquisition (2003)
15 slides from Getinge Ab Class B's merger presentation, 2003
Slide 1: Acquisition of Jostra Group
Acquisition of Jostra Group GETINGE has signed an agreement to purchase 100% of the shares of Jostra A.G. GETINGE will not acquire Jostra’s former US operations Jostra Bentley and Jostra Life Stream The acquisition is subject to German antitrust clearance which could be obtained within 4 - 5 weeks
Slide 2: Background Cardiovascular Disease
Background Cardiovascular Disease Leading cause of death and disability especially in developed countries and increasingly in emerging countries Blood pumps, oxygenerators and vascular access are the key technologies for cardiopulmonary by-pass. They have enabled the growth of cardiac surgery The nu
Slide 3: Background Cardiovascular Disease
Background Cardiovascular Disease Currently close to 90% of cardiac surgery is performed on-pump The Cardiopulmonary market is valued at approx. 4 500 MSEK and is expected to grow in mid- single digits - faster for Europe and emerging markets Heart valve procedures are growing faster and no off- pum
Slide 4: Jostra in brief
Jostra in brief Sales approx 90 M EUR in 2002 Associates ~ 600 Sales in 100 countries, own sales companies in: Germany, France, Italy, Japan, Canada, Spain, UK, Netherlands, Sweden, China, Hong Kong Production: Germany (2 sites), Sweden and Denmark Products: Heart lung machines, Oxygenators, Centrif
Slide 5: Products Hardware
Jostra Products Hardware HL 30 Perfusion Work Station HCU 30 Heater C
Slide 6: Disposables pediatric --> adult
Jostra Disposables pediatric --> adult Oxygenators Tubing sets Reservoirs Filters Cannulae / Catheters Centrifugal pumps
Slide 7: MECC: for minimal invasive On Pump Procedures
Jostra MECC: for minimal invasive On Pump Procedures On Pump 88 % minimally invasive on pump systems MECC Off Pump 12 % Traditional CPB MECC
Slide 8: RotaCell - Autotransfusion
Jostra RotaCell - Autotransfusion For collection, washing and reinfusion of patient blood Variable separation chamber - pediatrics Product not launched
Slide 9: Market Shares Heart-Lung Machines
Market Shares Heart-Lung Machines Snia 45% Jostra 25% Terumo 25% Others 5% Global market ~ 850 machines p.a.
Slide 10: Market Shares Oxygenators
Market Shares Oxygenators Worldwide Europe Snia 33% 43% Medtronic 20% 15% Jostra 13% 25% Terumo 12% 8% Others 22% 9% Global market ~ 1 200 000 pcs p.a.
Slide 11: Sales by Products
Sales by Products 3% 20% Heart-Lung machines MECC 10% Consumables Other 67% EUR 90 million
Slide 12: Sales Breakdown by Region 2002
Sales Breakdown by Region 2002 23% 26% Germany Other W. Europe Latin America 6% Africa 5% Asia/Pacific/Australia 40% EUR 90 million
Slide 13: Integration Focus and Targets
Jostra Integration Focus and Targets Integration of Jostra’s sales and marketing organisation with that of Surgical Systems Improved production structure Reinforce sales and marketing organisation to drive market penetration in Europe and emerging markets Focus the R&D pipeline to deliver new techno
Slide 14: Acquisition Financials
Jostra Acquisition Financials Price of shares 23.6 M EUR Assumed net debt 36.4 M EUR Restructuring costs: approx. 15 M EUR The goodwill amounts to 37 M EUR The target is to improve Jostra’s EBIT margin to 12 - 15% within 3 years after goodwill amortization Contribution to group earnings in 2003 will
Slide 15: Jostra future Opportunities
Jostra future Opportunities Entry into the autotransfusion market valued at 3 billion SEK Penetration with the minimal invasive MECC technology for on pump procedures and potentially for beating-heart procedures Improved market penetration through intensified sales and marketing efforts backed by go